Results 101 to 110 of about 561,014 (300)

Bioactivity of Thyroid Hormone Analogs at Cancer Cells

Frontiers in Endocrinology, 2018
In the context of genomic thyroid hormone actions in normal (noncancer) cells that involve primary interactions with nuclear thyroid hormone receptors (TRs), L-thyroxine (T4), and 3,3′,5′-triiodo-L-thyronine (reverse T3, rT3) have little bioactivity.
Paul J. Davis, Paul J. Davis, Heng-Yuan Tang, Aleck Hercbergs, Hung-Yun Lin, Hung-Yun Lin, Hung-Yun Lin, Hung-Yun Lin, Kelly A. Keating, Shaker A. Mousa   +9 more
doaj   +1 more source

Growth hormone-releasing hormone antagonists counteract hydrogen peroxide - induced paracellular hyperpermeability in endothelial cells. [PDF]

Growth Horm IGF Res, 2023
Barabutis N, Siejka A, Akhter MS.
europepmc   +1 more source

2,4-Diaminopyrimidine Derivatives as Potent Growth Hormone Secretagogue Receptor Antagonists

, 2016
Ghrelin, a gut-derived orexigenic hormone, is an endogenous ligand of the growth hormone secretagogue receptor (GHS-R). Centrally administered ghrelin has been shown to cause hunger and increase food intake in rodents.
Lissa T. J. Nelson (2507350), David W. A. Beno (2110654), Mei Liu (41760), Hongyu Zhao (4728), Eugene N. Bush (2533909), Zhili Xin (1909210), Gang Liu (81776), H. Douglas Falls (2533888), Michael D. Serby (2486734), Verlyn Schaefer (2642959), Brian A. Droz (2510449), Robin Shapiro (2521357), Christine A. Collins (2110648), Wiweka Kaszubska (2642965), Michael E. Brune (2110702), Peer B. Jacobson (2510416), Bo Liu (127343), Victoria E. Knourek-Segel (2533894), Theresa M. Turner (2642962), Bruce G. Szczepankiewicz (2047120), Hing L. Sham (2126860), Christi Kosogof (2533891), Thomas A. Fey (2465779)   +22 more
core   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Growth hormone-releasing hormone antagonists protect against hydrochloric acid-induced endothelial injury in vitro. [PDF]

Environ Toxicol Pharmacol, 2023
Barabutis N, Kubra KT, Akhter MS.
europepmc   +1 more source

Corticotropin-releasing hormone receptor antagonists

Corticotropin-releasing hormone (CRH), CRH-related peptides, and CRH receptors play major roles in coordinating the behavioral, endocrine, autonomic, and immune responses to stress.
Grammatopoulos, Dimitris, Chrousos, G. P., Zoumakis, E.   +2 more
core   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Potential uses of corticotropin-releasing hormone antagonists

, 2006
Corticotropin-releasing hormone (CRH), its natural homologs urocortins (UCN) 1, 2, and 3, and several types of CRH receptors (R), coordinate the behavioral, endocrine, autonomic, and immune responses to stress.
Gold, P. W., Chrousos, G. P., Zoumakis, E., Rice, K. C.   +3 more
core   +1 more source

Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists. [PDF]

Arab J Urol, 2021
Fragkoulis C, Glykas I, Dellis A, Mitsogiannis I, Papatsoris A.   +4 more
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source